Canada NewsWire
TORONTO, June 2, 2017
TORONTO, June 2, 2017 /CNW/ - Dr. Ali
Tehrani, President & Chief Executive Officer, Zymeworks Inc. (ZYME), joined Ungad Chadda, President, Capital
Formation, Equity Capital Markets, TMX Group to close the market. Zymeworks is a clinical-stage biopharmaceutical company
dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially
focused on the treatment of cancer. Zymeworks Inc. commenced trading on Toronto Stock Exchange on May 3, 2017.
SOURCE TMX Group Limited
View original content with multimedia: http://www.newswire.ca/en/releases/archive/June2017/04/c8990.html